Core Insights - Yinos Bio's stock price increased by 5.01% on September 17, reaching 45.28 CNY per share, with a trading volume of 1.21 billion CNY and a turnover rate of 3.06%, resulting in a total market capitalization of 6.384 billion CNY. The stock has risen for five consecutive days, with a cumulative increase of 14.8% during this period [1] Company Overview - Shanghai Yinos Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company went public on September 3, 2024. Its main business involves providing comprehensive research and development services (CRO) focused on non-clinical research services in biomedicine [1] - The revenue composition of Yinos Bio is as follows: non-clinical services account for 96.31%, clinical services for 3.42%, and other services for 0.27% [1] Shareholder Information - Among Yinos Bio's top ten circulating shareholders, one fund from Harvest Fund Management, the Harvest Medical Health Stock A (005303), entered the top ten in the second quarter, holding 344,300 shares, which represents 1.22% of the circulating shares. The estimated floating profit today is approximately 743,700 CNY, with a total floating profit of 1.9145 million CNY during the five-day increase [2] - The Harvest Medical Health Stock A fund was established on December 4, 2017, with a current scale of 786 million CNY. Year-to-date returns are 46.61%, ranking 574 out of 4222 in its category; the one-year return is 62.24%, ranking 1519 out of 3804; and since inception, the return is 99.77% [2] Fund Manager Performance - The fund manager of Harvest Medical Health Stock A is Sun Xiaohui, who has been in the position for 160 days, managing assets totaling 985 million CNY, with the best fund return during this period being 41.81% and the worst being 41.31% [3] - Co-manager Hao Miao has been in the role for 6 years and 246 days, managing assets of 3.652 billion CNY, with the best fund return during this period being 183.83% and the worst being -27.96% [3]
益诺思股价涨5.01%，嘉实基金旗下1只基金位居十大流通股东，持有34.43万股浮盈赚取74.37万元